Corcept Therapeutics (CORT) Tops Q3 EPS by 10c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $122.50 +1.20%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.30, $0.10 better than the analyst estimate of $0.20. Revenue for the quarter came in at $96.1 million versus the consensus estimate of $97.19 million.
GUIDANCE:
Corcept Therapeutics sees FY2021 revenue of $365-375 million, versus the consensus of $371 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Assumes Corcept Therapeutics (CORT) at Buy
- Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
